Effects of Arylsulfatase B and Pembrolizumab in Combination on Progression of Metastatic Melanoma in the B16F10 Syngeneic Mouse Model
Bhattacharyya, S.; O-Sullivan, I.; Tobacman, J. K.
Show abstract
In this report, experiments were performed to assess how Arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) treatment might interact with Pembrolizumab and improve therapeutic responses in melanoma. ARSB acts to remove 4-sulfate groups from chondroitin 4-sulfate (C4S; chondroitin sulfate A; CSA). ARSB is required for the degradation of C4S, identified as an oncofetal, tumor-agnostic antigen. Previous reports showed that in syngeneic B16F10 mouse melanomas, ARSB inhibited progression of subcutaneous and metastatic pulmonary melanomas and improved survival by direct effects on melanoma cells. ARSB enhanced apoptosis, which was mediated by increased expression of Constitutive Photomorphogenic (COP)1, an E3 ubiquitin ligase. Combined treatment by recombinant human ARSB, directed at melanoma cells, and Pembrolizumab, directed at infiltrating cytotoxic lymphocytes, can lead to increased apoptosis by different mechanisms, to declines in metalloproteinases and invasiveness, and to altered expression of cytokines. Synergism between effects of ARSB and Pembrolizumab may further inhibit the progression of melanoma and improve treatment outcomes.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Inhibition of the Myocardin-Related Transcription Factor pathway increases efficacy of Trametinib in NRAS-mutant melanoma cell lines 94%
- Transcriptional reprogramming and constitutive PD-L1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumor necrosis factor signaling pathways 94%
- Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model 94%
Similar papers in this journal
- Transcriptomic analysis of melanoma cells reveals an association of α-synuclein with regulation of the inflammatory response. 95%
- Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy 95%
- Knocking out alpha-synuclein in melanoma cells downregulates L1CAM and decreases motility 95%
Similar papers in this journal
- Pro-apoptotic and anti-invasive properties underscore the tumor suppressing impact of myoglobin on subset of human breast cancer cells 94%
- Kinase Suppressor of RAS 1 (KSR1) maintains the transformed phenotype of BRAFV600E mutant human melanoma cells 94%
- Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19 93%
Similar papers in this journal
- Blockade of Interleukin-6 (IL-6) Signaling in Dedifferentiated Liposarcoma (DDLPS) Decreases Mouse Double Minute 2 (MDM2) Oncogenicity via Alternative Splicing 95%
- Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma 95%
- Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the Bladder 94%
Similar papers in this journal
- The solute carrier MFSD1 decreases β1 integrins activation status and thus tumor metastasis 94%
- ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity 94%
- A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.